APLS
Apellis Pharmaceuticals, Inc.NASDAQHealthcare$40.41+0.54%ClosedMarket Cap: $5.17B
As of 2026-04-06
Valuation
P/E (TTM)
230.73
PEG
2.07
P/B
13.83
P/S
5.17
EV/EBITDA
74.47
DCF Value
$-1,865.26
FCF Yield
0.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.8%
Operating Margin
5.5%
Net Margin
2.2%
ROE
8.2%
ROA
2.1%
ROIC
6.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $199.9M | 85.1% | $-51.1M | $-59.0M | $-0.47 | — |
| FY 2025 | $1.00B | 89.8% | $55.4M | $22.4M | $0.18 | — |
| Q3 2025 | $458.6M | 94.7% | $223.2M | $215.7M | $1.71 | — |
| Q2 2025 | $178.5M | 92.1% | $-33.3M | $-42.2M | $-0.33 | — |
| Q1 2025 | $166.8M | 79.4% | $-83.3M | $-92.2M | $-0.74 | — |
| Q4 2024 | $212.5M | 80.8% | $-26.2M | $-36.4M | $-0.29 | — |
| FY 2024 | $781.4M | 84.9% | $-165.0M | $-197.9M | $-1.60 | — |
| Q3 2024 | $196.8M | 83.0% | $-47.3M | $-57.4M | $-0.46 | — |
| Q2 2024 | $199.7M | 88.2% | $-29.4M | $-37.7M | $-0.30 | — |
| Q1 2024 | $172.3M | 88.0% | $-62.1M | $-66.4M | $-0.54 | — |
| Q4 2023 | $146.4M | 86.4% | $-84.5M | $-88.6M | $-0.73 | — |
| FY 2023 | $396.6M | 85.2% | $-517.1M | $-528.6M | $-4.45 | — |